Tesamorelin
Growth Hormone SecretagoguesSynthetic GHRH analog FDA-approved for reducing visceral adipose tissue in HIV patients, powerful for stubborn abdominal fat.
Key Benefits
- ✓Significant reduction in visceral fat
- ✓Improved lipid profiles
- ✓Enhanced GH production
- ✓Better insulin sensitivity
- ✓Preserved lean muscle mass
- ✓Improved body composition
Dosing Information
Detailed Protocol
Administered via subcutaneous injection, typically in the abdomen. Injected once daily, preferably in the morning. Reconstitution required.
About Tesamorelin
Tesamorelin is a synthetic form of growth hormone-releasing hormone containing all 44 amino acids of native GHRH. It was specifically developed and approved by the FDA for treatment of excess abdominal fat in HIV patients with lipodystrophy. It has gained attention for its ability to reduce visceral fat while preserving subcutaneous fat.
Research Notes
FDA-approved in 2010 for HIV-associated lipodystrophy. Clinical trials demonstrated significant reduction in visceral adipose tissue (VAT) with minimal effect on subcutaneous fat.
Potential Side Effects
- •Injection site reactions
- •Joint pain
- •Peripheral edema
- •Muscle pain
- •Possible glucose intolerance
Always consult with a healthcare professional before starting any peptide therapy.